Clinical Trial

Study Of KITE-753 in R/R B-Cell ALL

Name: Study Of KITE-753 in R/R B-Cell ALL — clinical trial record (NCT07674823)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.

Trial Details

NCT Number	NCT07674823
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Kite, A Gilead Company
Conditions	B-cell Acute Lymphoblastic Leukemia
Enrollment	18 participants
Start Date	2026-12-31
Primary Completion	2029-04-01 (estimated)
Study Completion	2031-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-30